278 related articles for article (PubMed ID: 22039253)
1. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
Fabarius A; Leitner A; Hochhaus A; Müller MC; Hanfstein B; Haferlach C; Göhring G; Schlegelberger B; Jotterand M; Reiter A; Jung-Munkwitz S; Proetel U; Schwaab J; Hofmann WK; Schubert J; Einsele H; Ho AD; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Lauseker M; Pfirrmann M; Hasford J; Saussele S; Hehlmann R;
Blood; 2011 Dec; 118(26):6760-8. PubMed ID: 22039253
[TBL] [Abstract][Full Text] [Related]
2. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
Crisan AM; Coriu D; Arion C; Colita A; Jardan C
J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
[TBL] [Abstract][Full Text] [Related]
4. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
Millot F; Dupraz C; Guilhot J; Suttorp M; Brizard F; Leblanc T; Güneş AM; Sedlacek P; De Bont E; Li CK; Kalwak K; Lausen B; Culic S; Dworzak M; Kaiserova E; De Moerloose B; Roula F; Biondi A; Baruchel A; Guilhot F
Cancer; 2017 Sep; 123(18):3609-3616. PubMed ID: 28497898
[TBL] [Abstract][Full Text] [Related]
5. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.
Fabarius A; Kalmanti L; Dietz CT; Lauseker M; Rinaldetti S; Haferlach C; Göhring G; Schlegelberger B; Jotterand M; Hanfstein B; Seifarth W; Hänel M; Köhne CH; Lindemann HW; Berdel WE; Staib P; Müller MC; Proetel U; Balleisen L; Goebeler ME; Dengler J; Falge C; Kanz L; Burchert A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Brümmendorf TH; Edinger M; Hofmann WK; Pfirrmann M; Hasford J; Krause S; Hochhaus A; Saußele S; Hehlmann R;
Ann Hematol; 2015 Dec; 94(12):2015-24. PubMed ID: 26385387
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of cytogenetic monitoring in chronic myeloid leukemia].
Pan CY; Xu N; He BL; Cao R; Liao LB; Yin CX; Lan YQ; Lu ZY; Huang JX; Sun J; Feng R; Liu QF; Liu XL
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):112-117. PubMed ID: 28279034
[No Abstract] [Full Text] [Related]
7. Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches.
Asnafi AA; Deris Zayeri Z; Shahrabi S; Zibara K; Vosughi T
J Cell Physiol; 2019 May; 234(5):5798-5806. PubMed ID: 30430567
[TBL] [Abstract][Full Text] [Related]
8. Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations.
Asif M; Hussain A; Wali A; Ahmed N; Ali I; Iqbal Z; Amir M; Shafiq M; Rasool M
Anal Cell Pathol (Amst); 2021; 2021():4909012. PubMed ID: 34422550
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.
Johansson B; Fioretos T; Mitelman F
Acta Haematol; 2002; 107(2):76-94. PubMed ID: 11919388
[TBL] [Abstract][Full Text] [Related]
10. The cytogenetic scenario of chronic myeloid leukemia.
Mitelman F
Leuk Lymphoma; 1993; 11 Suppl 1():11-5. PubMed ID: 8251885
[TBL] [Abstract][Full Text] [Related]
11. Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.
Bozkurt S; Uz B; Buyukasik Y; Bektas O; Inanc A; Goker H; Kansu E
Med Oncol; 2013 Mar; 30(1):443. PubMed ID: 23292838
[TBL] [Abstract][Full Text] [Related]
12. Presence of Additional Cytogenetic Abnormality of t(1;15) at Diagnosis of Chronic Myelogenous Leukemia-Chronic Phase.
Ji M; Hur M; Kim HN; Moon HW; Yun YM; Kim SY; Han SH
Ann Clin Lab Sci; 2016 May; 46(3):308-11. PubMed ID: 27312558
[TBL] [Abstract][Full Text] [Related]
13. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Cytogenetic Aberrations in the Clonal Evolution of Chronic Myeloid Leukemia: A Single-Center Experience Among 450 Turkish Patients (Cohort Study).
Işık S; Günden G; Üsküdar Teke H; Akay OM; Oğuz Davutoğlu N; Aslan V; Karagülle M; Özen H; Çilingir O; Artan S; Durak Aras B
Turk J Haematol; 2022 Dec; 39(4):237-244. PubMed ID: 36199265
[TBL] [Abstract][Full Text] [Related]
15. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression.
Clark RE; Apperley JF; Copland M; Cicconi S
Blood Adv; 2021 Feb; 5(4):1102-1109. PubMed ID: 33616651
[TBL] [Abstract][Full Text] [Related]
16. Rare monosomy 7 and deletion 7p at diagnosis of chronic myeloid leukemia in accelerated phase.
Alswied A; Rehman A; Lai LW; Duran J; Sardar M; Proytcheva MA
Cancer Genet; 2021 Apr; 252-253():111-114. PubMed ID: 33497941
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha].
Hong H; Qiu JY; Lai YY; Shi Y; He Q; Dang H; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):269-73. PubMed ID: 12844411
[TBL] [Abstract][Full Text] [Related]
18. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.
Zaccaria A; Testoni N; Valenti AM; Luatti S; Tonelli M; Marzocchi G; Cipriani R; Baldazzi C; Giannini B; Stacchini M; Gamberini C; Castagnetti F; Rosti G; Azzena A; Cavazzini F; Cianciulli AM; Dalsass A; Donti E; Giugliano E; Gozzetti A; Grimoldi MG; Ronconi S; Santoro A; Spedicato F; Zanatta L; Baccarani M;
Cancer Genet Cytogenet; 2010 Jun; 199(2):76-80. PubMed ID: 20471509
[TBL] [Abstract][Full Text] [Related]
19. Determination of secondary chromosomal aberrations of chronic myelocytic leukemia.
Wang Y; Hopwood VL; Hu P; Lennon A; Osterberger J; Glassman A
Cancer Genet Cytogenet; 2004 Aug; 153(1):53-6. PubMed ID: 15325094
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Wang W; Cortes JE; Tang G; Khoury JD; Wang S; Bueso-Ramos CE; DiGiuseppe JA; Chen Z; Kantarjian HM; Medeiros LJ; Hu S
Blood; 2016 Jun; 127(22):2742-50. PubMed ID: 27006386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
